Keensight, Eres acquire Biovian

The company's founders and managers also invested in the deal.

Eres is a branch of the Edmond de Rothschild group making minority investments in growth companies. It is investing from its Eres III fund, closed in 2016 on €300m. The fund targets deals with an enterprise value between €100m-2bn, deploying between €10-45m per transaction.

Keensight held a final close for its latest fund, Keensight IV, on its hard-cap of €250m in 2014. Keensight IV invests €10-30m in European companies with revenues of €15-150m. The firm span out from the Rothschild group in 2013.

The company plans to use the fresh funding and support to increase capacity, expand and further internationalise its current client base, and bolster its products portfolio along a one-stop-shop concept for clients.

Company
Established in 2003, Biovian engages in the contract development and manufacturing of biopharmaceuticals using microbial, mammalian and viral production platforms. End products manufactured at Biovian include recombinant proteins, antibody fragments and gene-therapy vectors targeted for unmet medical needs.

People
Keensight Capital – Magdalena Svensson (partner).

Advisers
Company – Achelous Partners (M&A).
Equity – Evli Corporate Finance (M&A); William Blair (M&A).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Buyouts
• France
• Healthcare
• Keensight Capital
• France